Literature DB >> 18185522

E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia.

C-h Zhong1, V Prima, X Liang, C Frye, L McGavran, L Meltesen, Q Wei, T Boomer, M Varella-Garcia, J Gump, S P Hunger.   

Abstract

A 5-year-old boy who initially presented with ALL and relapsed 4 months later with AML was found to have an add(19) in the leukemia cells. FISH revealed that the add(19) was really a cryptic t(l2;l9)(p13.3;p13.3) interrupting E2A (TCF3). Nucleotide sequences of cloned genomic fragments with the E2A rearrangements revealed that the der(12) contained E2A joined to an intron of the NOLI (p120) gene. Reverse transcriptase (RT)-PCR of patient lymphoblast RNA showed expression of in-frame fusion cDNAs consisting of most of NOL1 fused to the 3' portion of E2A that encoded part of the second transcriptional activation domain and the DNA binding and protein dimerization motifs. The reciprocal der(19) E2A genomic rearrangements included 5' regions of E2A joined to an intron of the ZNF384 (NMP4, CIZ) gene, located approximately 450 kb centromeric to NOL1 on chromosome 12. RT-PCR showed expression of in-frame E2A-ZNF384 fusion cDNAs. To our knowledge, this is the second report of a chromosome translocation in leukemia resulting in two different gene fusions. This is the first report of expression of E2A fusion protein that includes the DNA binding and protein dimerization domains due to a more proximal break in E2A compared to those described previously.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185522     DOI: 10.1038/sj.leu.2405084

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.

Authors:  Y Gocho; N Kiyokawa; H Ichikawa; K Nakabayashi; T Osumi; T Ishibashi; H Ueno; K Terada; K Oboki; H Sakamoto; Y Shioda; M Imai; Y Noguchi; Y Arakawa; Y Kojima; D Toyama; K Hata; T Yoshida; K Matsumoto; M Kato; T Fukushima; K Koh; A Manabe; A Ohara
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

2.  ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.

Authors:  Shinsuke Hirabayashi; Kentaro Ohki; Kazuhiko Nakabayashi; Hitoshi Ichikawa; Yukihide Momozawa; Kohji Okamura; Akinori Yaguchi; Kazuki Terada; Yuya Saito; Ai Yoshimi; Hiroko Ogata-Kawata; Hiromi Sakamoto; Motohiro Kato; Junya Fujimura; Moeko Hino; Akitoshi Kinoshita; Harumi Kakuda; Hidemitsu Kurosawa; Keisuke Kato; Ryosuke Kajiwara; Koichi Moriwaki; Tsuyoshi Morimoto; Kozue Nakamura; Yasushi Noguchi; Tomoo Osumi; Kazuo Sakashita; Junko Takita; Yuki Yuza; Koich Matsuda; Teruhiko Yoshida; Kenji Matsumoto; Kenichiro Hata; Michiaki Kubo; Yoichi Matsubara; Takashi Fukushima; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara; Nobutaka Kiyokawa
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

3.  EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.

Authors:  Akinori Yaguchi; Takeshi Ishibashi; Kazuki Terada; Hitomi Ueno-Yokohata; Yuya Saito; Junya Fujimura; Toshiaki Shimizu; Kentaro Ohki; Atsushi Manabe; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490

Review 4.  Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage.

Authors:  Lindsey E Montefiori; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

5.  Leukemia With TCF3-ZNF384 Rearrangement as a Distinct Subtype of Disease With Distinct Treatments: Perspectives From A Case Report and Literature Review.

Authors:  Na Lin; Xiaojing Yan; Dali Cai; Lei Wang
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

6.  Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.

Authors:  Nana Ping; Huiying Qiu; Qian Wang; Haiping Dai; Changgeng Ruan; Stefan Ehrentraut; Hans G Drexler; Roderick A F MacLeod; Suning Chen
Journal:  J Hematol Oncol       Date:  2015-08-21       Impact factor: 17.388

7.  Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.

Authors:  Maoxiang Qian; Hui Zhang; Shirley Kow-Yin Kham; Shuguang Liu; Chuang Jiang; Xujie Zhao; Yi Lu; Charnise Goodings; Ting-Nien Lin; Ranran Zhang; Takaya Moriyama; Zhaohong Yin; Zhenhua Li; Thuan Chong Quah; Hany Ariffin; Ah Moy Tan; Shuhong Shen; Deepa Bhojwani; Shaoyan Hu; Suning Chen; Huyong Zheng; Ching-Hon Pui; Allen Eng-Juh Yeoh; Jun J Yang
Journal:  Genome Res       Date:  2016-11-30       Impact factor: 9.043

8.  Histotype-specific copy-number alterations in ovarian cancer.

Authors:  Ruby Yunju Huang; Geng Bo Chen; Noriomi Matsumura; Hung-Cheng Lai; Seiichi Mori; Jingjing Li; Meng Kang Wong; Ikuo Konishi; Jean-Paul Thiery; Liang Goh
Journal:  BMC Med Genomics       Date:  2012-10-18       Impact factor: 3.063

9.  Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer.

Authors:  Iñigo Ortiz de Mendíbil; José L Vizmanos; Francisco J Novo
Journal:  PLoS One       Date:  2009-03-12       Impact factor: 3.240

10.  EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.

Authors:  Akifumi Endo; Daisuke Tomizawa; Yuki Aoki; Tomohiro Morio; Shuki Mizutani; Masatoshi Takagi
Journal:  Cancer Sci       Date:  2016-11-25       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.